BRAF and metastatic melanoma: In June 2018, the FDA approved the combination of BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for treatment of patients with unresectable or metastatic melanoma with a BRAF-V600E or -V600K mutation.